JAK2 and hepatocellular carcinoma: This interaction leads to a significant reduction in the phosphorylation of downstream signaling pathways, including focal adhesion kinase (FAK) and janus kinase 2 (JAK2), which was the main target market for acacetin [95] in the human hepatocellular carcinoma cell line, HepG2.